Reata Announces FDA Accepted for Filing the NDA for Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport Syndrome

PLANO, Texas, April 26, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the“Company,” or“we”), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news